StocksMediumUpdated×5•Originally published 9 November 2026•Updated 10 November 2026•
4 min read

Senseonics Revenue Jumps 140% to $19.6 Million, Raises 2026 Outlook

By

Key Facts

1Third-quarter revenue was $19.6 million, up nearly 140% from $8.1 million a year earlier.
2The company raised its 2026 revenue guidance to $68–70 million from $62–66 million, with expected annual growth of 93% to 98%.
3Gross profit was $12.1 million and margin was about 62%, compared with $3.5 million and a 43% margin in the third quarter of 2025.
4The net loss widened to $32.7 million, or $0.50 per share, compared with $19.5 million and $0.43 per share a year earlier.

Senseonics said on November 9 that third-quarter 2026 revenue was $19.6 million, up nearly 140% from $8.1 million in the year-earlier period. The company raised its full-year revenue outlook to $68–70 million from $62–66 million, implying expected annual growth of 93% to 98%. Chief Executive Tim Goodnow said the quarter’s growth "reflects the progress we are making in executing our commercial strategy and increasing awareness and demand for Eversense 365." The quarterly figures provide a basis for the higher outlook, while the new guidance sets a higher bar for commercial performance during the rest of the year. The revenue outlook increase coincided with a higher estimate for full-year gross margin of more than 60%.

Gross profit was $12.1 million in the third quarter, with a gross margin of about 62%, compared with profit of $3.5 million and a margin of 43% in the third quarter of 2025. In its full-year guidance, Senseonics raised its margin forecast to more than 60%, from its previous range of 58% to 61%. This reflects an improvement in the share of revenue remaining after the cost of sales, alongside an increase in gross profit in dollar terms. Company data showed gross margin was 61.7% in the three months ended September 30, compared with 42.8% a year earlier. In its report, the company attributed the improvement to favorable margins on sales of the 365-day product, higher sales through the consignment network with a pricing advantage, the elimination of the previous revenue share, stable manufacturing costs, and the transition from Eversense E3 to Eversense 365 in Europe.

Revenue growth came alongside a widening of the net loss to $32.7 million, or $0.50 per share, compared with $19.5 million, or $0.43 per share, in the year-earlier period. Selling, general and administrative expenses rose to $32.3 million from $15.3 million, and the company said the increase reflected the ongoing costs of its commercial organization in the United States and Europe. Research and development expenses also rose to $11.7 million, compared with $7.8 million a year earlier. The company linked research spending to continued clinical trials for the Gemini system and development work on Freedom. As of September 30, cash and cash equivalents, restricted cash and short-term investments totaled $126.6 million, while the carrying value of debt was about $56.2 million, including $55.0 million of loan principal.

Revenue growth also extended through the first nine months of the year, reaching $45.8 million through September 30, compared with $21.0 million in the same period of 2025. In its report, Senseonics attributed the increase to growth in its U.S. patient base, marketing and treatment-access initiatives, and demand for the 365-day product. In terms of patient access, the EON Care network included more than 100 sensor insertion specialists during the third quarter. Network members performed more than 40% of Eversense insertions during the quarter, and the company raised its target for the network to 120 specialists by year-end. The company links expansion of this network to making insertion procedures available within its commercial infrastructure, while the numbers of specialists and procedures indicate the scale of its activity during the period.

Revenue exceeded the analyst consensus estimate of $16.2 million, according to Investing.com. The loss per share was $0.50, below the estimated loss of $0.52 per share. SENS shares closed at $9.80 on November 9, according to the same source. Investing.com also reported that the stock had risen 26.780% over the preceding three months and 54.820% over 12 months through that date. These figures place the session’s performance within the stock’s trajectory over both periods, without by themselves determining the effect of the company’s results on its price movements.

In product development, Senseonics began its first human study of the investigational Freedom glucose monitoring system, designed to communicate directly with a mobile device without a component worn on the body. The company said research and development expenses include continued clinical activity for the Gemini system and work on Freedom development. On commercial integration, Senseonics and Beta Bionics plan to launch integration of Eversense 365 with the iLet system during the fourth quarter of 2026. The planned launch remains subject to completion of integration work and applicable requirements. The company had scheduled a call to review third-quarter results for November 9 at 4:30 p.m. Eastern Time, with a simultaneous webcast.

Sources

Open on chart